Don’t miss the latest developments in business and finance.

Ajanta Pharma Q4 PAT falls 5% to Rs 151 cr; revenue rises to Rs 870 cr

Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.

Ajanta Pharma's API facility in Waluj, Aurangabad (Maharashtra)
For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.
Press Trust of India New Delhi
1 min read Last Updated : May 10 2022 | 7:26 PM IST

Ajanta Pharma on Tuesday said its consolidated profit after tax declined by 5 per cent to Rs 151 crore for the fourth quarter ended March 2022.

The drug firm had reported a consolidated PAT (Profit After Tax) of Rs 159 crore in the January-March quarter of 2020-21 fiscal.

Revenue from operations rose to Rs 870 crore during the period under review from Rs 757 crore in the year-ago period, the Mumbai-based drug firm said in a regulatory statement.

For the year ended March 31, 2022, the company posted a PAT of Rs 713 crore. It was Rs 654 crore in FY21. Revenue from operations rose to Rs 3,341 crore last fiscal as against Rs 2,890 crore in 2020-21.

The company said its board has approved the issuance of bonus equity shares in the proportion of 1 share of Rs 2 each for every 2 shares of Rs 2 each.

Also Read

Topics :Ajanta PharmaQ4 Results

First Published: May 10 2022 | 7:26 PM IST

Next Story